FORWARD Study of GORE VIABAHN Balloon-Expandable Endoprostheses and Bare Metal Stents in the United States, European Union, United Kingdom, Australia, and New Zealand When Placed to Treat Complex Iliac Occlusive Disease: Protocol for a Randomized Superiority Trial (Preprint)
Authors:
- Melissa L KirkwoodMKMelissa L Kirkwood
- Ehrin J ArmstrongEAEhrin J Armstrong
- Mohammad M AnsariMAMohammad M Ansari
- Andrew HoldenAHAndrew Holden
- Michel M P J ReijnenMRMichel M P J Reijnen
- Markus SteinbauerMSMarkus Steinbauer
- Zachary CrannellZCZachary Crannell
- Hector NovoaHNHector Novoa
- Austin PhillipsAPAustin Phillips
- Darren B SchneiderDSDarren B Schneider
Preprint
- 1 August 2023
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. OBJECTIVE The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. METHODS A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. RESULTS Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. CONCLUSIONS The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. CLINICALTRIAL ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/51480Keywords
All Related Versions
- Published version: JMIR Research Protocols, 12 (1), e51480.
This publication has 22 references indexed in Scilit:
- Covered vs Uncovered Stents for Aortoiliac and Femoropopliteal Arterial DiseaseJournal of Endovascular Therapy, 2016
- Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, Criqui MH. Ethnic-specific Prevalence of Peripheral Arterial Disease in the United States. Am J Prev Med 2007;32(4):328–33.American Journal of Preventive Medicine, 2014
- Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations)Circulation, 2013
- Measurement and Interpretation of the Ankle-Brachial IndexCirculation, 2012
- DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trialTrials, 2012
- A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive diseaseJournal of Vascular Surgery, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Acute and Long-term Outcome of Endovascular Therapy for Aortoiliac Occlusive Lesions Stratified According to the TASC Classification:A Single-Center ExperienceJournal of Endovascular Therapy, 2008
- Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patientsJournal of Vascular Surgery, 2006
- Prevalence of and Risk Factors for Peripheral Arterial Disease in the United StatesCirculation, 2004